Lung cancer patients' CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

Cancer Immunology, Immunotherapy

Volumn 57, Issue 10, 2008, Pages 1493-1504

  Srivastava, Minu K ^a   Bosch, Jacobus J ^a   Thompson, James A ^a   Ksander, Bruce R ^b   Edelman, Martin J ^c   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CD4+ T lymphocytes; Cell based cancer vaccine; Lung cancer; Major histocompatibility complex class II; Myeloid derived suppressor cells

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CANFOSFAMIDE; CARBOPLATIN; CD11B ANTIGEN; CD33 ANTIGEN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; GENETIC TRANSFECTION; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

BLOTTING, WESTERN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MYELOID CELLS;

EID: 48149107380     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0490-9     Document Type: Article

References (47)

1. B Almand JI Clark E Nikitina J van Beynen NR English SC Knight DP Carbone DI Gabrilovich 2001 Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer J Immunol 166 678 689
2. TD Armstrong VK Clements BK Martin JP Ting S Ostrand-Rosenberg 1997 Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity Proc Natl Acad Sci USA 94 6886 6891
3. D Atanackovic NK Altorki E Stockert B Williamson AA Jungbluth E Ritter D Santiago CA Ferrara M Matsuo A Selvakumar B Dupont YT Chen EW Hoffman G Ritter LJ Old S Gnjatic 2004 Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients J Immunol 172 3289 3296
4. S Baskar L Glimcher N Nabavi RT Jones S Ostrand-Rosenberg 1995 Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice J Exp Med 181 619 629
5. JJ Bosch JA Thompson MK Srivastava UK Iheagwara TG Murray M Lotem BR Ksander S Ostrand-Rosenberg 2007 MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells Cancer Res 67 4499 4506
6. V Bronte M Wang WW Overwijk DR Surman F Pericle SA Rosenberg NP Restifo 1998 Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells J Immunol 161 5313 5320
7. C Butts N Murray A Maksymiuk G Goss E Marshall D Soulieres Y Cormier P Ellis A Price R Sawhney M Davis J Mansi C Smith D Vergidis M MacNeil M Palmer 2005 Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 6674 6681
8. EA Danna P Sinha M Gilbert VK Clements BA Pulaski S Ostrand-Rosenberg 2004 Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease Cancer Res 64 2205 2211
9. SK Dissanayake JA Thompson JJ Bosch VK Clements PW Chen BR Ksander S Ostrand-Rosenberg 2004 Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy Cancer Res 64 1867 1874
10. P Filipazzi R Valenti V Huber L Pilla P Canese M Iero C Castelli L Mariani G Parmiani L Rivoltini 2007 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine J Clin Oncol 25 2546 2553
11. OJ Finn 2003 Cancer vaccines: between the idea and the reality Nat Rev Immunol 3 630 641
12. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res 67:425; author reply 426
13. EA Hirschowitz T Foody GE Hidalgo JR Yannelli 2007 Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells Lung Cancer 57 365 372
14. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host Cancer Res 66 1123 1131
15. + T cells are required for secondary expansion and memory in CD8+ T lymphocytes Nature 421 852 856
16. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66
17. ML Kaufman HLDisis 2004 Immune system versus tumor: shifting the balance in favor of DCs and effective immunity J Clin Invest 113 664 667
18. N Koch GH Wong JW Schrader 1984 Ia antigens and associated invariant chain are induced simultaneously in lines of T-dependent mast cells by recombinant interferon-gamma J Immunol 132 1361 1369
19. F Kong RL Jirtle DH Huang RW Clough MS Anscher 1999 Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma Cancer 86 1712 1719
20. S Kusmartsev DI Gabrilovich 2002 Immature myeloid cells and cancer-associated immune suppression Cancer Immunol Immunother 51 293 298
21. SA Kusmartsev Y Li SH Chen 2000 Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation J Immunol 165 779 785
22. JJ Letterio AB Roberts 1998 Regulation of immune responses by TGF-beta Annu Rev Immunol 16 137 161
23. A Muntasell M Carrascal I Alvarez L Serradell P van Veelen FA Verreck F Koning J Abian D Jaraquemada 2004 Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands J Immunol 173 1085 1093
24. J Nemunaitis 2007 A review of vaccine clinical trials for non-small cell lung cancer Expert Opin Biol Ther 7 89 102
25. J Nemunaitis RO Dillman PO Schwarzenberger N Senzer C Cunningham J Cutler A Tong P Kumar B Pappen C Hamilton E DeVol PB Maples L Liu T Chamberlin DL Shawler H Fakhrai 2006 Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 4721 4730
26. J Nemunaitis T Jahan H Ross D Sterman D Richards B Fox D Jablons J Aimi A Lin K Hege 2006 Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Ther 13 555 562
27. J Nemunaitis D Sterman D Jablons JW Smith II B Fox P Maples S Hamilton F Borellini A Lin S Morali K Hege 2004 Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer J Natl Cancer Inst 96 326 331
28. D O'Mahony S Kummar ME Gutierrez 2005 Non-small-cell lung cancer vaccine therapy: a concise review J Clin Oncol 23 9022 9028
29. BA Pulaski S Ostrand-Rosenberg 1998 Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res 58 1486 1493
30. LE Raez PA Cassileth JJ Schlesselman S Padmanabhan EZ Fisher PA Baldie K Sridhar ER Podack 2003 Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma Cancer Gene Ther 10 850 858
31. LE Raez PA Cassileth JJ Schlesselman K Sridhar S Padmanabhan EZ Fisher PA Baldie ER Podack 2004 Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer J Clin Oncol 22 2800 2807
32. LE Raez JD Rosenblatt ER Podack 2006 Present and future of lung cancer vaccines Expert Opin Emerg Drugs 11 445 459
33. TC Ramos EN Vinageras MC Ferrer BG Verdecia IL Rupale LM Perez GG Marinello RP Rodriguez AL Davila 2006 Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial Cancer Biol Ther 5 145 149
34. P Serafini C De Santo I Marigo S Cingarlini L Dolcetti G Gallina P Zanovello V Bronte 2004 Derangement of immune responses by myeloid suppressor cells Cancer Immunol Immunother 53 64 72
35. DJ Shedlock H Shen 2003 Requirement for CD4 T cell help in generating functional CD8 T cell memory Science 300 337 339
36. FA Shepherd 2000 Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices J Clin Oncol 18 35S 38S
37. J Shimizu S Yamazaki S Sakaguchi 1999 Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity J Immunol 163 5211 5218
38. P Sinha V Clements SK Bunt SM Albelda Ostrand-Rosenberg 2007 Cross-talk between myeloid-derived suppressor cells and macorphages subverts tumor immunity towards a type 2 response J Immunol 179 977 983
39. P Sinha VK Clements S Ostrand-Rosenberg 2005 Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease J Immunol 174 636 645
40. V Steimle CA Siegrist A Mottet B Lisowska-Grospierre B Mach 1994 Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA Science 265 106 109
41. S Strober 1984 Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships Annu Rev Immunol 2 219 237
42. E Suzuki V Kapoor AS Jassar LR Kaiser SM Albelda 2005 Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 6713 6721
43. M Terabe S Matsui JM Park M Mamura N Noben-Trauth DD Donaldson W Chen SM Wahl S Ledbetter B Pratt JJ Letterio WE Paul JA Berzofsky 2003 Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence J Exp Med 198 1741 1752
44. JA Thompson SK Dissanayake BR Ksander KL Knutson ML Disis S Ostrand-Rosenberg 2006 Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain Cancer Res 66 1147 1154
45. JA Thompson MK Srivastava JJ Bosch V Clements BR Ksander S Ostrand-Rosenberg 2007 The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes Cancer Immunol Immunother 57 389 398
46. MR Young DM Lathers 1999 Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers Int J Immunopharmacol 21 241 252
47. AH Zea PC Rodriguez MB Atkins C Hernandez S Signoretti J Zabaleta D McDermott D Quiceno A Youmans A O'Neill J Mier AC Ochoa 2005 Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion Cancer Res 65 3044 3048